Our group previously reported that IL-13 treatment of bronchial epithelial cells reduced SARS-CoV2 replication in donors with allergic asthma and not healthy children (34), suggesting there may be differential responses to IL-13 in rhinovirus between healthy and asthmatic epithelium. The gene discussed is IL13; the disease is allergic asthma.